Watch now

NEW MEDICINES, NOVEL INSIGHTS

Advancing precision oncology

Download the executive summary

Gwyn Bebb, M.D., BM, BCh, Ph.D.

Senior Vice President, Global Therapeutic Area Head – Oncology

Read bio

Precision oncology will continue to be a slow unfurling. Patients are our guides and partners in this quest. Ideal precision oncology therapies deliver maximum benefits with minimum off-target effects and are universally accessible. This report examines some obstacles drug developers encounter and describes strategies to help bring precision cancer medicines more quickly and certainly to market—to benefit an ever-increasing proportion of patients.

FEATURED EDITORIAL

We will realize the vision of precision oncology by solving one challenge at a time.

By Gwyn Bebb, M.D., BM, BCh, Ph.D., Senior Vice President and Global Therapeutic Area Head - Oncology

Precision oncology, with its vision of treating each patient with the exact right medicine, is within reach yet still remote. This paradox has forever hung over my career as an academic researcher, oncologist, and biopharmaceutical industry executive.

Read more

IN THIS REPORT

SECTION 1

Empowering cancer patients

Empowering cancer patients

Patients and society won’t reap the benefits of precision oncology unless we democratize the data. Patients need access to genetic tests and test results and the ability to quickly identify which clinical trials they are eligible for. We could achieve this and empower patients with a few practical improvements to current care pathways.

Go to section

SECTION 2

Regulatory Strategies

Regulatory Strategies

Co-developing a companion diagnostic and conducting thorough dose optimization studies are but two of the regulatory challenges facing precision oncology drug developers. Sponsors can de-risk their interactions with regulators by systematically removing uncertainties and finding the most efficient, least burdensome regulatory path.

Go to section

SECTION 3

Development Discussions

Development Discussions

Two forces are increasing efficiency in precision oncology development. Recent advances in multi-omics and computational analytics are expediting the discovery and validation of biomarkers. Expanding clinical trials to regional and community sites is helping sponsors achieve faster enrollment times, more diverse patient populations, and the same high-quality trial data.

Go to section

SECTION 4

Market Access

Market Access

Improving health outcomes for cancer patients increasingly depends on access to biomarker testing. Rapid advancements in biomarker discovery and testing capabilities are at a tipping point that will significantly impact the development of new precision oncology therapies in the pipeline.

Go to section